BioLife Solutions, Inc. (BLFS)
35.25
-0.28
(-0.79%)
USD |
NASDAQ |
Sep 04, 16:00
34.81
-0.44
(-1.25%)
After-Hours: 20:00
BioLife Solutions Research and Development Expense (Quarterly) : 2.958M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.958M |
| March 31, 2026 | 2.65M |
| December 31, 2025 | -0.067M |
| September 30, 2025 | 2.709M |
| June 30, 2025 | 1.965M |
| March 31, 2025 | 1.439M |
| December 31, 2024 | 1.183M |
| September 30, 2024 | 1.893M |
| June 30, 2024 | 2.029M |
| March 31, 2024 | 2.075M |
| December 31, 2023 | 3.06M |
| September 30, 2023 | 3.739M |
| June 30, 2023 | 3.793M |
| March 31, 2023 | 4.152M |
| December 31, 2022 | 4.164M |
| September 30, 2022 | 3.425M |
| June 30, 2022 | 3.428M |
| March 31, 2022 | 3.781M |
| December 31, 2021 | 3.571M |
| September 30, 2021 | 3.219M |
| June 30, 2021 | 3.045M |
| March 31, 2021 | 1.987M |
| December 31, 2020 | 1.854M |
| September 30, 2020 | 1.725M |
| June 30, 2020 | 1.477M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.663M |
| December 31, 2019 | 0.748M |
| September 30, 2019 | 1.032M |
| June 30, 2019 | 0.691M |
| March 31, 2019 | 0.359M |
| December 31, 2018 | 0.315M |
| September 30, 2018 | 0.312M |
| June 30, 2018 | 0.3246M |
| March 31, 2018 | 0.3465M |
| December 31, 2017 | 0.295M |
| September 30, 2017 | 0.2931M |
| June 30, 2017 | 0.3186M |
| March 31, 2017 | 0.2868M |
| December 31, 2016 | 0.428M |
| September 30, 2016 | 0.4969M |
| June 30, 2016 | 0.599M |
| March 31, 2016 | 0.5042M |
| December 31, 2015 | 0.4258M |
| September 30, 2015 | 0.3295M |
| June 30, 2015 | 0.3013M |
| March 31, 2015 | 0.3222M |
| December 31, 2014 | 0.3577M |
| September 30, 2014 | 0.1533M |
| June 30, 2014 | 0.1928M |
| March 31, 2014 | 0.1673M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Repligen Corp. | 14.42M |
| Agilent Technologies, Inc. | 120.00M |
| Danaher Corp. | 412.00M |
| Thermo Fisher Scientific, Inc. | 364.00M |
| West Pharmaceutical Services, Inc. | 19.70M |